Incubate Featured in STAT's Coverage of the EPIC Act Introduction

STAT reporter Ed Silverman recently interviewed Incubate's execute director John Stanford for an article on the EPIC Act's reintroduction in the House.

The EPIC Act would undo a discrepancy in the Inflation Reduction Act that has shifted the investment away from small molecule therapies, despite their enormous scientific potential. In STAT, Stanford explains how the bill would restore balance in incentives for drug development:

"As a life science investor, the most glaring error in the law, from our perspective, is a false and arbitrary difference in reward based on the type of drug," said John Stanford, who heads Incubate, a group of venture capitalists...

"The impact of the IRA is that you get four more years of profit if you choose to invest in a biologic and that pills are worth less. So if I'm sitting on a $100 million fund or a $1 billion fund, I can have a nine-year profit window or a 13-year profit window. But somewhere between 40% to 50% of returns come in years 10 to 13 after a drug hits the market because investment is recouped during those earlier years."